Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men
- 1 February 1991
- journal article
- Published by Wiley in Journal of Internal Medicine
- Vol. 229 (2) , 125-130
- https://doi.org/10.1111/j.1365-2796.1991.tb00319.x
Abstract
The aim of this study was to evaluate the effect of treatment with subcutaneous injections of recombinant human erythropoietin (rhEpo), 20-40 IU kg−1 body weight, 3 times a week, on resting blood pressure, blood pressure response during submaximal exercise, some haematological parameters, and subjective side-effects in 15 healthy male subjects. RhEpo increased both haemoglobin (Hb) concentration and haematocrit (Hct) significantly, the values for Hb being 152 ± 4.2 g l−1 before treatment and 169 ± 9.3 g l−1 (mean values ± SD) after 6 weeks of rhEpo treatment (P < 0.001). The corresponding values for Hct were 44.5 ± 1.5% and 49.7 ± 1.9% (P < 0.001), respectively. The systolic and diastolic blood pressure values at rest were unchanged after rhEpo treatment. A marked increase in systolic blood pressure was observed during submaximal exercise at 200 W, the initial and final values being 177 ± 14.2 mmHg and 191 ± 19.5 mmHg (P < 0.01), respectively. Heart rate during exercise at 200 W was significantly lower after rhEpo treatment than before it: 144 ± 15 beats min−1 compared to 136 ± 8 beats min−1 (P < 0.001). The leucocyte count remained unchanged after rhEpo treatment, but there was a significant decrease (P< 0.05) in the number of lymphocytes. Reticulocyte and platelet counts were unchanged. Serum (S) ferritin decreased from 87.3 ± 41.8 mmol l−1 to 59.3 ± 27.8 mmol l−1 after rhEpo treatment (P < 0.001). Serum-Na, S-K, S-Ca, S-creatinine, S-bilirubin, S-aspartate aminotranferase (ASAT), S-alanine aminotranferase (ALAT), and S-lactate dehydrogenase (LD) were unchanged after rhEpo treatment. No subjective side-effects were reported. In conclusion, low doses of rhEpo increased Hb levels and Hct by more than 10% after 6 weeks. Blood pressure at rest was unchanged, but rhEpo induced a markedly accentuated blood pressure reaction during exercise. A minor decrease in the lymphocyte count was observed, but electrolyte and creatinine levels remained unchanged after rhEpo treatment.Keywords
This publication has 13 references indexed in Scilit:
- Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietinThe Lancet, 1990
- The Use of Recombinant Human Erythropoietin in the Correction of Anemia in Predialysis Patients and Its Effect on Renal Function: A Double-Blind, Placebo-Controlled TrialAmerican Journal of Kidney Diseases, 1989
- Effects of blood transfusions on some hematological variables in endurance athletesMedicine & Science in Sports & Exercise, 1989
- Beneficial effects of erythropoietin on haematological parameters, aerobic capacity, and body fluid composition in patients on haemodialysisJournal of Internal Medicine, 1989
- Increased Preoperative Collection of Autologous Blood with Recombinant Human Erythropoietin TherapyNew England Journal of Medicine, 1989
- Erythropoietin und HypertonieKlinische Wochenschrift, 1988
- Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass.Proceedings of the National Academy of Sciences, 1988
- Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.BMJ, 1987
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- The Influence of Physical Training and Other Factors on the Subjective Rating of Perceived ExertionActa Physiologica Scandinavica, 1971